[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension-diagnosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100475637","phase-3-doxycycline-host-directed-therapy-to-improve-lung-function-and-decrease-tissue-destruction-in-pulmonary-tuberculosis-100475637",false,"NCT05473520","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)","Doxy-TB","The recruitment target would be 150 patients, with 75 in each arm\n\nInclusion criteria: Patients should meet all criteria:\n\n1. Aged 21 years and above\n2. Patients receiving ≤ 14 days of TB treatment or about to start standard combination TB treatment\n3. Confirmed pulmonary TB with positive acid-fast bacilli smear and\u002For positive nucleic acid amplification test (NAAT) and\u002For TB culture results\n4. CXR demonstrating pulmonary involvement with cavity or cavities\n5. Able to provide informed consent\n\nExclusion criteria:\n\n1. HIV co-infection\n2. Previous pulmonary TB\n3. Severe, pre-existing lung disease such as pulmonary fibrosis, bronchiectasis, COPD and lung cancer\n4. Pregnant or breast feeding\n5. Allergies to tetracyclines\n6. Patients on retinoic acid, neuromuscular blocking agents and pimozide which may increase risk of drug toxicity\n7. Autoimmune disease and\u002For on systemic immunosuppressants\n8. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of study drug, or planned use during the study period\n9. Enrolment in any other clinical trial involving a systemic drug or intervention involving the lung\n10. Evidence of severe depression, schizophrenia or mania\n11. ALT \\> 3 times upper limit of normal\n12. Creatinine \\> 2 times upper limit of normal\n13. Principal investigator assessment of lack of willingness to participate and comply with all requirements including follow-up of the protocol, or identification of any factor felt to significantly increase the participant's risk of suffering an adverse outcome","ALL","21 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD). A recent Phase 2b double-blind randomised-controlled clinical trial shows that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue damaging enzyme activity and decreases pulmonary cavity volume (1). We aim to determine if adjunctive doxycycline can reduce PIAT and improve cardiovascular outcomes in a fully powered Phase III trial of 8 weeks of adjunctive doxycycline alongside standard pulmonary TB (PTB) treatment.\n\nThe investigators hypothesize that doxycycline inhibits tissue destruction in patients with PTB and thereby leads to improved lung function after treatment.\n\nSpecific aims\n\n1. To assess improvement in lung function as measured by forced expiratory volume (FEV1) predicted in PTB patients given doxycycline versus placebo.\n2. To investigate whether doxycycline will hasten the resolution of pulmonary cavities measured by CT thorax\n3. To investigate whether doxycycline can suppress inflammatory markers including matrix metalloproteinases\n4. To investigate whether doxycycline can accelerate time to sputum conversion\n5. To evaluate the effect of doxycycline on cardiovascular outcomes such as the incidence of acute coronary syndrome (ACS) and pulmonary hypertension\n6. To investigate whether doxycycline improves TB drug concentrations in sputum and plasma.\n7. To assess the safety profile of doxycycline with concurrent standard anti-tuberculous treatment.",[27,28,29],"Tuberculosis","Acute Coronary Syndrome","Pulmonary Hypertension (Diagnosis)","RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":34},"2023-05-24",{"date":38,"type":21},"2030-01-31",{"name":40,"class":41},"National University Hospital, Singapore","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100597359","prospective-evaluation-of-ai-ecg-for-shd-detection-100597359","NCT07057466","Prospective Evaluation of AI-ECG for SHD Detection","Prospective Evaluation of Artificial Intelligence-enhanced Electrocardiography for Detection of Structural Heart Disease","AI-ECG-SHD","Inclusion Criteria:\n\n* Patients aged 18-90 years\n* No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe arrhythmia or unstable cardiovascular disease\n* Prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD\n* Cardiac implantable electronic device in-situ, including a permanent pacemaker or implantable cardioverter defibrillator\n* Involvement in current research or recent involvement in any research prior to recruitment",true,"18 Years","90 Years",{"count":55,"type":21},590,"OBSERVATIONAL","This study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (ECGs), to detect heart problems. These tests can be done using both traditional ECG machines and portable, wearable devices like smartwatches, making it easier for people to monitor their heart health at home.\n\nWhile AI has shown promise using past data, this study will involve the collection of ECG data and subsequent testing of its accuracy in real-world settings to ensure it works well for both doctors and patients. The goal is to see if AI can identify conditions like heart muscle weakness, valve issues, and high lung pressure from the ECG data of patients. The researchers will also compare AI's detections with other blood tests commonly used to diagnose heart disease.\n\nThe AI models that will be used are being tested for research and validation purposes only. They will not be used for clinical decision-making or providing information to influence diagnosis, treatment, or patient care during the study. The AI outputs are not shared with clinicians and will have no impact on the care pathway.\n\nThis research will demonstrate if AI-powered ECG analysis - whether from traditional or portable devices - can provide a low-cost, non-invasive way to detect heart disease early and improve health assessments.",[59,29,60,61],"Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)","Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis)","Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)",[63,64,65,66,67,68,69,70,71],"Artificial Intelligence","Machine Learning","Wearable Devices","Portable Devices","Heart Failure","Pulmonary Hypertension","Valvular Heart Disease","Echocardiography","Electrocardiography","2026-03-06",{"date":74,"type":34},"2026-03-09",{"date":76,"type":34},"2025-11-04",{"date":78,"type":21},"2027-08-02",{"name":80,"class":41},"Imperial College London",5,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100619406","guard-ph-guided-use-of-ai-ecg-for-risk-detection-of-ph-in-surgery-guard-ph-trial-100619406","NCT07344207","GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial)","A Prospective, Open-Label, Randomized Controlled Trial of an Artificial Intelligence Enabled Electrocardiography System for Preoperative Detection of Pulmonary Hypertension and Related Diseases(GUARD-PH)","GUARD-PH","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients scheduled for non-cardiac surgery under general anesthesia.\n3. Patients who have a scheduled standard preoperative electrocardiogram (ECG).\n4. Patients capable of understanding the study and willing to provide medical records for research purposes, and who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients scheduled for emergency surgery.\n2. Patients who explicitly refuse to participate or withdraw consent.\n3. Patients with specific comorbidities that interfere with ECG interpretation or data collection (e.g., implanted pacemakers).",{"count":91,"type":21},1380,[93],"NA","This study is a prospective, open-label, randomized controlled trial designed to evaluate a new artificial intelligence (AI) tool for heart monitoring. Researchers will use an AI-enabled electrocardiography (ECG) system to screen patients before they undergo surgery. The main goal is to determine if this AI system can accurately detect pulmonary hypertension and related heart diseases in the preoperative setting. The study is being conducted at Taipei Veterans General Hospital.",[29,96,97,98],"Pre-operative Assessment","Postoperative Complications (Cardiopulmonary)","Treatment Outcomes",[63,71,100,101,102],"AI-ECG","Preoperative Detection","Screening","NOT_YET_RECRUITING","2026-01-07",{"date":106,"type":34},"2026-01-15",{"date":108,"type":21},"2026-01-05",{"date":110,"type":21},"2027-01-05",{"name":112,"class":113},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1]